LivaNova PLC (NASDAQ:LIVN) Director Daniel Jeffrey Moore sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $96.63, for a total value of $144,945.00. The transaction was disclosed in a filing with the SEC, which is available through this link.
Daniel Jeffrey Moore also recently made the following trade(s):
- On Friday, February 15th, Daniel Jeffrey Moore sold 1,500 shares of LivaNova stock. The shares were sold at an average price of $100.44, for a total value of $150,660.00.
- On Tuesday, January 15th, Daniel Jeffrey Moore sold 1,500 shares of LivaNova stock. The shares were sold at an average price of $90.80, for a total value of $136,200.00.
LivaNova stock traded down $0.08 during mid-day trading on Tuesday, hitting $95.29. The company’s stock had a trading volume of 235,300 shares, compared to its average volume of 528,430. The company has a market capitalization of $4.67 billion, a PE ratio of 30.06, a price-to-earnings-growth ratio of 2.87 and a beta of 0.87. The company has a quick ratio of 0.76, a current ratio of 1.07 and a debt-to-equity ratio of 0.09. LivaNova PLC has a one year low of $79.96 and a one year high of $131.54.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, February 27th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.10 by $0.02. The company had revenue of $297.00 million for the quarter, compared to the consensus estimate of $294.98 million. LivaNova had a positive return on equity of 9.64% and a negative net margin of 17.11%. LivaNova’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.88 EPS. As a group, research analysts anticipate that LivaNova PLC will post 3.22 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the business. Financial Gravity Companies Inc. bought a new position in LivaNova in the 4th quarter valued at $60,000. Bamco Inc. NY bought a new position in LivaNova in the 3rd quarter valued at $143,000. South Dakota Investment Council bought a new position in LivaNova in the 4th quarter valued at $110,000. Ffcm LLC purchased a new stake in shares of LivaNova in the 4th quarter worth $133,000. Finally, Meeder Asset Management Inc. lifted its holdings in shares of LivaNova by 130.8% in the 4th quarter. Meeder Asset Management Inc. now owns 1,632 shares of the company’s stock worth $148,000 after buying an additional 925 shares during the period. 89.49% of the stock is currently owned by institutional investors.
Several research firms have recently weighed in on LIVN. BTIG Research reissued a “hold” rating on shares of LivaNova in a research report on Tuesday, March 5th. BidaskClub downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of LivaNova in a research report on Wednesday, February 27th. ValuEngine downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 28th. Finally, Zacks Investment Research raised LivaNova from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $128.75.
WARNING: “Insider Selling: LivaNova PLC (LIVN) Director Sells 1,500 Shares of Stock” was posted by Zolmax and is owned by of Zolmax. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://zolmax.com/investing/insider-selling-livanova-plc-livn-director-sells-1500-shares-of-stock/2975357.html.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Featured Story: Why is a lock-up period needed for an IPO?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.